A clinical trial of dextromethorphan in amyotrophic lateral sclerosis
Introduction - Although the cause of amyotrophic lateral sclerosis (ALS) is unknown, excitotoxicity mediated by glutamate has been implicated. Dextromethorphan is a NMDA-glutamate receptor antagonist with neuroprotective properties. Material and methods - The effect of treatment with dextromethorpha...
Wedi'i Gadw mewn:
Prif Awduron: | Ole Gredal, Lene Werdelin, S. Bąk, Peter Brøgger Christensen, Gudrun Boysen, Michael Kristensen, Jesper Jespersen, Lisbeth Regeur, H H Hinge, Troels S. Jensen |
---|---|
Fformat: | Artigo |
Iaith: | Saesneg |
Cyhoeddwyd: |
2009
|
Mynediad Ar-lein: | https://doi.org/10.1111/j.1600-0404.1997.tb00231.x |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Eitemau Tebyg
-
A pilot trial of dextromethorphan in amyotrophic lateral sclerosis.
gan: Askmark, H, et al.
Cyhoeddwyd: (1993) -
Human CCS gene: genomic organization and exclusion as a candidate for amyotrophic lateral sclerosis (ALS)
gan: Silahtaroglu, Asli N, et al.
Cyhoeddwyd: (2002) -
The size distribution of neurons in the motor cortex in amyotrophic lateral sclerosis
gan: Toft, Mette Helene, et al.
Cyhoeddwyd: (2005) -
Amyotrophic Lateral Sclerosis and Exposure to Diesel Exhaust in a Danish Cohort
gan: Dickerson, Aisha S, et al.
Cyhoeddwyd: (2018) -
Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis
gan: Marianthi‐Anna Kioumourtzoglou, et al.
Cyhoeddwyd: (2015)